27 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Mar 2038. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Mar 2038
Next term end
14
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends no later than Aug 2039 · Medium confidence
Also notable
Ends Aug 2040 · Medium confidence
Also notable
Ends Mar 2039 · Medium confidence
Also notable
Ends Sep 2040 · Low confidence
Also notable
Ends Dec 2038 · High confidence
Also notable
Ends Jun 2042 · High confidence
Also notable
Ends May 2042 · High confidence
Novel CRISPR RNA Targeting Enzymes and Systems and Uses Thereof
US 11,168,322
Cited by 34 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2039. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Novel CRISPR-Associated Systems and Components
US 11,667,904
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2040.
Novel CRISPR DNA Targeting Enzymes and Systems
US 10,808,245
Cited by 9 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2039.
Novel CRISPR DNA Targeting Enzymes and Systems
US 11,453,867
A family of 6 related applications built on the 2022 grant. Protection runs to 2040. A terminal disclaimer caps this term to an earlier patent's.
Novel CRISPR DNA Targeting Enzymes and Systems
US 11,447,771
A family of 5 related applications built on the 2022 grant. Protection runs to 2038.
Gene Editing Systems Comprising an RNA Guide Targeting Hydroxyacid Oxidase 1 (HAO1) and Uses Thereof
US 11,821,012
Granted 2023. Computed term ends 2042. A terminal disclaimer caps this term to an earlier patent's.
Novel CRISPR DNA and RNA Targeting Enzymes and Systems
US 12,195,770
Granted 2025. Too new for citation comparison; protection runs to 2042.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 27, 2027The maintenance fee for Novel CRISPR RNA Targeting Enzymes and Systems and Uses Thereof (US 10,392,616) comes due Feb 27, 2027. Unpaid by Aug 27, 2027, it lapses early.
- 1 fee due Apr 24, 2027The maintenance fee for Novel CRISPR DNA Targeting Enzymes and Systems (US 11,795,442) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due May 21, 2027The maintenance fee for Gene Editing Systems Comprising an RNA Guide Targeting Hydroxyacid Oxidase 1 (HAO1) and Uses Thereof (US 11,821,012) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Jul 9, 2027The maintenance fee for Compositions Comprising a Variant CAS12I4 Polypeptide and Uses Thereof (US 11,866,746) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Novel CRISPR DNA Targeting Enzymes and Systems (US 11,912,992) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 26, 2027The maintenance fee for Gene Editing Systems Comprising an RNA Guide Targeting Lactate Dehydrogenase a (LDHA) and Uses Thereof (US 11,939,607) comes due Sep 26, 2027. Unpaid by Mar 27, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Compositions Comprising a Variant Polypeptide and Uses Thereof (US 11,946,045) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
- 1 fee due Nov 7, 2027The maintenance fee for Novel CRISPR DNA Targeting Enzymes and Systems (US 11,976,308) comes due Nov 7, 2027. Unpaid by May 8, 2028, it lapses early.
Recent changes
- Nov 11Assignment recorded on 1 record: Haswell, Jeffrey Raymond and 4 others to Arbor Biotechnologies, Inc. Recorded Nov 11, 2026, executed Jun 20, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76716, frame 662.
- Nov 4Assignment recorded on 1 record: Alfonse, Lauren E. and 3 others to Arbor Biotechnologies, Inc. Recorded Nov 4, 2026, executed Apr 29, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76627, frame 409.
- 3 of the patents on this record were granted since Aug 23, 2026
What they patent
The largest of its 14 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,392,616 | Novel CRISPR RNA Targeting Enzymes and Systems and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,447,771 | Novel CRISPR DNA Targeting Enzymes and Systems In force · High confidence | In force | High confidence | |
| US 11,643,654 | Novel CRISPR DNA Targeting Enzymes and Systems In force · High confidence | In force | High confidence | |
| US 12,553,045 | Novel CRISPR DNA Targeting Enzymes and Systems In force · High confidence | In force | High confidence | |
| US 10,808,245 | Novel CRISPR DNA Targeting Enzymes and Systems In force · Medium confidence | In force | Medium confidence | |
| US 11,168,324 | Novel CRISPR DNA Targeting Enzymes and Systems In force · Low confidence | In force | Low confidence | |
| US 11,912,992 | Novel CRISPR DNA Targeting Enzymes and Systems In force · Low confidence | In force | Low confidence | |
| US 11,168,322 | Novel CRISPR RNA Targeting Enzymes and Systems and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 11,667,904 | Novel CRISPR-Associated Systems and Components In force · Medium confidence | In force | Medium confidence | |
| US 12,716,060 | Novel CRISPR-Associated Systems and Components In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 27: 45 applications pending · 17 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.